Pharmaceuticals

An analysis of Chiesi’s H1 results reveals a strategy where strategic acquisitions and deep R&D investment drive both profit and a €6B economic footprint.

As leaders of Prestige Consumer Healthcare prepare for a key investor conference, all eyes are on their strategy for leveraging iconic brands in a complex market.

With a key conference appearance, OPKO Health aims to translate its deep R&D pipeline into market confidence. Will investors buy into its long-term vision?

QuVa Pharma's acquisition of CAPS's portfolio aims to secure vital drug supplies, but it also highlights the immense pressure and regulatory risks in this market.

New AI-powered analysis of Endeavor BioMedicines' taladegib shows significant lung volume gains, offering a glimmer of hope for reversing damage in IPF.

Keke Palmer partners with Sanofi to promote an RSV antibody for babies. We explore the breakthrough science and the ethical tightrope of celebrity health advocacy.

While we focus on breakthrough drugs, the real story is often in the logistics. GCCL’s expansion into Asia-Pacific highlights the critical, and lucrative, world of clinical trial support.

A landmark bill in Congress and nationwide walks aim to channel millions into R&D for a genetic disorder affecting 500,000 Americans, creating a new roadmap for a cure.

A breakthrough drug for a rare disease gets a key nod, but its high price tag forces a showdown between patient need and Canada's public purse.

Cipla and Qilu are teaming up to launch a biosimilar for Keytruda, the world's top cancer drug, signaling a major shift in patient access and market dynamics.

A deep dive into PRF Technologies' audacious dual-engine strategy, as it simultaneously pushes for FDA trials and commercializes AI for the green energy grid.

As Claris Bio courts investors, it's not just capital on the line. At stake is a first-of-its-kind eye drop for a rare, blinding disease.

With a new cancer drug showing promise but cash reserves dwindling, Citius Pharma's CEO faces a critical test: convincing investors the pipeline is worth the risk.

The prestigious Prix Galien awards debut in Seoul, cementing South Korea's status as a life sciences leader and spotlighting a wave of homegrown innovation.

With Hepatitis C royalties declining, Enanta Pharmaceuticals faces investors this month to sell its vision: a future built on novel RSV and immunology drugs.

An estimated 13 million Americans live with Dupuytren's contracture, a progressive hand condition. A new campaign using mixed reality aims to change that.

Telehealth firm NexLife is disrupting the GLP-1 market with flat-rate pricing and novel sublingual options, a strategy aimed at accessibility amid regulatory scrutiny.

UCB's landmark agreement with the U.S. government trades pricing concessions for tariff exemptions, signaling a major shift in industry strategy.

A strategic merger combines Chemomab's promising drug, nebokitug, with Scipher's AI platform, aiming to de-risk development and transform RA treatment.

XYRA's new trial uses data from wearables to personalize doses of Budiodarone, a safer alternative to today's standard AF drugs. Is this the future?